- Home
- Na Molecular Point Of Care Testing Using Naat Market
NA Molecular Point of Care Testing (Using NAAT) Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-171 | No of pages: 286 | Format:
North America molecular point of care testing (using NAAT) market is projected to register a substantial CAGR of 12.1% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020, and the forecast period is 2021 to 2028.
Market Segmentation:
North America Molecular Point of Care Testing (Using NAAT), By Product (Instruments And Consumables And Reagents), Indication (Respiratory Infections Testing, Sexually Transmitted Infection (STI) Testing, Gastrointestinal Tract Infections Testing And Others), End User ( Laboratories, Hospitals, Clinics, Home Care, Ambulatory Centers, Assisted Living Facilities And Others), Mode Of Testing ( Prescription-Based Testing And OTC-Based Testing), Distribution Channel (Direct Sales, Third Party Distributors, Online Sales), Country (U.S. and Canada)- Industry Trends and Forecast to 2028
Some of the major factors contributing to the growth of the North America molecular point of care testing (using NAAT) market are:
Increasing healthcare expenditure
Increasing Prevalence of chronic diseases
Market Players:
Some of the key market players for North America molecular point of care testing (using NAAT) market are listed below:
Thermo Fisher Scientific Inc.
Hologic, Inc.
BD
F. Hoffmann-La Roche Ltd
ABBOTT
Seegene Inc.
bioMrieux SA
QIAGEN
Bio-Rad Laboratories, Inc.
PerkinElmer Inc.
Grifols, S.A.
Quidel Corporation
GenMark Diagnostics, Inc.
SD Biosensor, INC.
Oxford Nanopore Technologies
Wondfo
Randox Laboratories Ltd.
Meridian Bioscience
Sekisui Diagnostics
QuantuMDx Group Ltd.
Lucira Health Inc.
binx health, inc.
Sysmex (A Subsidiary of Sysmex Corporation)
Co-Diagnostics, Inc.
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 42
1.1 OBJECTIVES OF THE STUDY 42
1.2 MARKET DEFINITION 42
1.3 OVERVIEW OF NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET 42
1.4 LIMITATIONS 44
1.5 MARKETS COVERED 44
2 MARKET SEGMENTATION 46
2.1 MARKETS COVERED 46
2.2 GEOGRAPHICAL SCOPE 47
2.3 YEARS CONSIDERED FOR THE STUDY 48
2.4 CURRENCY AND PRICING 48
2.5 DBMR TRIPOD DATA VALIDATION MODEL 49
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 52
2.7 MULTIVARIATE MODELLING 53
2.8 DISTRIBUTION CHANNEL LIFELINE CURVE 53
2.9 DBMR MARKET POSITION GRID 54
2.10 VENDOR SHARE ANALYSIS 56
2.11 MARKET END USER COVERAGE GRID 57
2.12 SECONDARY SOURCES 58
2.13 ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 62
4.1 PORTERS FIVE FORCES 63
4.2 PESTEL ANALYSIS 64
4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES 65
4.3.1 CEPHEID 65
4.3.2 THERMO FISHER SCIENTIFIC INC. 66
4.3.3 HOLOGIC, INC. 67
4.3.4 BD 68
4.3.5 F. HOFFMANN-LA ROCHE LTD 69
4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY 70
4.5 PRICE PER POCT INSTRUMENT 71
4.5.1 NORTH AMERICA 71
4.5.2 EUROPE 73
4.5.3 SOUTH ASIA 74
4.5.4 SOUTH EAST ASIA 76
4.5.5 MIDDLE EAST 79
4.5.6 AFRICA 81
4.6 PRICE PER TEST 83
4.6.1 NORTH AMERICA 83
4.6.2 EUROPE 91
4.6.3 SOUTH ASIA 99
4.6.4 SOUTH EAST ASIA 107
4.6.5 MIDDLE EAST 119
4.6.6 AFRICA 131
4.7 MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS 139
4.8 MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) 143
4.9 MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS 147
4.10 MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS 150
4.11 DISTRIBUTORS 153
4.11.1 NORTH AMERICA 153
4.11.2 EUROPE 154
4.11.3 SOUTH ASIA 156
4.11.4 SOUTH EAST ASIA 157
4.11.5 MIDDLE EAST 159
4.11.6 AFRICA 160
5 REGULATORY FRAMEWORK 161
6 MARKET OVERVIEW 164
6.1 DRIVERS 166
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES 166
6.1.2 IMPROVING DIAGNOSIS SEEKING RATE 166
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS 167
6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE 167
6.1.5 RISING PREFERENCE FOR HOMECARE TESTING 168
6.2 RESTRAINTS 169
6.2.1 PRODUCT RECALLS 169
6.2.2 HIGH COSTS OF PRODUCTS 169
6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS 170
6.3 OPPORTUNITIES 170
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 170
6.3.2 RISING HEALTHCARE EXPENDITURE 171
6.3.3 PANDEMIC OUTBREAK OF COVID-19 172
6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS 172
6.4 CHALLENGES 173
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES 173
6.4.2 LACK OF ACCESSIBILITY 173
7 IMPACT OF COVID-19 ON THE NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET 175
7.1 IMPACT ON PRICE 175
7.2 IMPACT ON DEMAND 175
7.3 IMPACT ON SUPPLY CHAIN 176
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19 176
7.5 CONCLUSION: 177
8 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT 178
8.1 OVERVIEW 179
8.2 CONSUMABLES & REAGENTS 182
8.3 INSTRUMENTS 182
8.3.1 MOBILE PLATFORM (SMALL & PORTABLE) 183
8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM) 183
9 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION 184
9.1 OVERVIEW 185
9.2 RESPIRATORY INFECTIONS TESTING 188
9.2.1 COVID-19 189
9.2.2 FLU B 189
9.2.3 FLU A 189
9.2.4 RSV 189
9.2.5 TUBERCULOSIS 189
9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA) 189
9.2.7 OTHERS 190
9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING 190
9.3.1 TV 191
9.3.2 CT 191
9.3.3 NG 191
9.3.4 HPV 191
9.3.5 HSV 191
9.3.6 MG 191
9.3.7 UU 192
9.3.8 MH 192
9.3.9 OTHERS 192
9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING 192
9.4.1 GROUP B STREPTOCOCCUS 193
9.4.2 SHIGA TOXIN 193
9.4.3 H. PYLORI 193
9.5 OTHERS 194
10 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER 195
10.1 OVERVIEW 196
10.2 LABORATORIES 199
10.3 HOSPITAL 199
10.4 CLINICS 200
10.5 AMBULATORY CENTER 201
10.6 HOMECARE 201
10.7 ASSISTED LIVING FACILITIES 202
10.8 OTHERS 203
11 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING 204
11.1 OVERVIEW 205
11.2 PRESCRIPTION-BASED TESTING 208
11.3 OTC TESTING 209
12 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL 210
12.1 OVERVIEW 211
12.2 DIRECT SALES 214
12.3 THIRD PARTY DISTRIBUTOR 214
12.4 ONLINE SALES 215
13 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION 216
13.1 NORTH AMERICA 217
13.1.1 U.S. 224
13.1.2 CANADA 228
14 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE 232
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 232
15 SWOT ANALYSIS 233
16 COMPANY PROFILE 234
16.1 DANAHER 234
16.1.1 COMPANY SNAPSHOT 234
16.1.2 REVENUE ANALYSIS 234
16.1.3 COMPANY SHARE ANALYSIS 235
16.1.4 PRODUCT PORTFOLIO 235
16.1.5 RECENT DEVELOPMENTS 236
16.2 THERMO FISHER SCIENTIFIC INC. 237
16.2.1 COMPANY SNAPSHOT 237
16.2.2 REVENUE ANALYSIS 237
16.2.3 COMPANY SHARE ANALYSIS 238
16.2.4 PRODUCT PORTFOLIO 238
16.2.5 RECENT DEVELOPMENTS 238
16.3 HOLOGIC, INC. 239
16.3.1 COMPANY SNAPSHOT 239
16.3.2 REVENUE ANALYSIS 239
16.3.3 COMPANY SHARE ANALYSIS 240
16.3.4 PRODUCT PORTFOLIO 240
16.3.5 RECENT DEVELOPMENTS 240
16.4 BD 241
16.4.1 COMPANY SNAPSHOT 241
16.4.2 REVENUE ANALYSIS 241
16.4.3 COMPANY SHARE ANALYSIS 242
16.4.4 PRODUCT PORTFOLIO 242
16.4.5 RECENT DEVELOPMENTS 242
16.5 F.HOFFMANN-LA-ROCHE LTD. 243
16.5.1 COMPANY SNAPSHOT 243
16.5.2 REVENUE ANALYSIS 243
16.5.3 COMPANY SHARE ANALYSIS 244
16.5.4 PRODUCT PORTFOLIO 244
16.5.5 RECENT DEVELOPMENTS 245
16.6 ABBOTT 246
16.6.1 COMPANY SNAPSHOT 246
16.6.2 REVENUE ANALYSIS 246
16.6.3 PRODUCT PORTFOLIO 247
16.6.4 RECENT DEVELOPMENTS 247
16.7 BINX HEALTH, INC. 248
16.7.1 COMPANY SNAPSHOT 248
16.7.2 PRODUCT PORTFOLIO 248
16.7.3 RECENT DEVELOPMENT 248
16.8 BIOMERIEUX SA 249
16.8.1 COMPANY SNAPSHOT 249
16.8.2 REVENUE ANALYSIS 249
16.8.3 PRODUCT PORTFOLIO 250
16.8.4 RECENT DEVELOPMENT 250
16.9 BIO-RAD LABORATORIES, INC. 251
16.9.1 COMPANY SNAPSHOT 251
16.9.2 REVENUE ANALYSIS 251
16.9.3 PRODUCT PORTFOLIO 252
16.9.4 RECENT DEVELOPMENTS 252
16.10 CO-DIAGNOSTICS, INC. 254
16.10.1 COMPANY SNAPSHOT 254
16.10.2 REVENUE ANALYSIS 254
16.10.3 PRODUCT PORTFOLIO 255
16.10.4 RECENT DEVELOPMENTS 255
16.11 GENMARK DIAGNOSTICS, INC 256
16.11.1 COMPANY SNAPSHOT 256
16.11.2 REVENUE ANALYSIS 256
16.11.3 PRODUCT PORTFOLIO 257
16.11.4 RECENT DEVELOPMENT 257
16.12 GRIFOLS, S.A. 258
16.12.1 COMPANY SNAPSHOT 258
16.12.2 REVENUE ANALYSIS 258
16.12.3 PRODUCT PORTFOLIO 259
16.12.4 RECENT DEVELOPMENT 259
16.13 LUCIRA HEALTH INC. 260
16.13.1 COMPANY SNAPSHOT 260
16.13.2 PRODUCT PORTFOLIO 260
16.13.3 RECENT DEVELOPMENTS 260
16.14 MERIDIAN BIOSCIENCE 261
16.14.1 COMPANY SNAPSHOT 261
16.14.2 REVENUE ANALYSIS 261
16.14.3 PRODUCT PORTFOLIO 262
16.14.4 RECENT DEVELOPMENTS 262
16.15 OXFORD NANOPORE TECHNOLOGIES 263
16.15.1 COMPANY SNAPSHOT 263
16.15.2 PRODUCT PORTFOLIO 263
16.15.3 RECENT DEVELOPMENT 263
16.16 PERKIN ELMER INC. 264
16.16.1 COMPANY SNAPSHOT 264
16.16.2 REVENUE ANALYSIS 264
16.16.3 PRODUCT PORTFOLIO 265
16.16.4 RECENT DEVELOPMENT 265
16.17 QIAGEN 266
16.17.1 COMPANY SNAPSHOT 266
16.17.2 REVENUE ANALYSIS 266
16.17.3 PRODUCT PORTFOLIO 267
16.17.4 RECENT DEVELOPMENTS 267
16.18 QUANTUMDX GROUP LTD. 269
16.18.1 COMPANY SNAPSHOT 269
16.18.2 PRODUCT PORTFOLIO 269
16.18.3 RECENT DEVELOPMENTS 269
16.19 QUIDEL CORPORATION 271
16.19.1 COMPANY SNAPSHOT 271
16.19.2 REVENUE ANALYSIS 271
16.19.3 PRODUCT PORTFOLIO 272
16.19.4 RECENT DEVELOPMENT 272
16.20 RANDOX LABORATORIES LTD. 273
16.20.1 COMPANY SNAPSHOT 273
16.20.2 PRODUCT PORTFOLIO 273
16.20.3 RECENT DEVELOPMENTS 273
16.21 SD BIOSENSOR, INC. 275
16.21.1 COMPANY SNAPSHOT 275
16.21.2 PRODUCT PORTFOLIO 275
16.21.3 RECENT DEVELOPMENT 275
16.22 SEEGENE INC, 276
16.22.1 COMPANY SNAPSHOT 276
16.22.2 REVENUE ANALYSIS 276
16.22.3 PRODUCT PORTFOLIO 277
16.22.4 RECENT DEVELOPMENT 277
16.23 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL) 278
16.23.1 COMPANY SNAPSHOT 278
16.23.2 PRODUCT PORTFOLIO 278
16.23.3 RECENT DEVELOPMENT 278
16.24 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION 280
16.24.1 COMPANY SNAPSHOT 280
16.24.2 REVENUE ANALYSIS 280
16.24.3 PRODUCT PORTFOLIO 281
16.24.4 RECENT DEVELOPMENT 281
16.25 WONDFO 282
16.25.1 COMPANY SNAPSHOT 282
16.25.2 PRODUCT PORTFOLIO 282
16.25.3 RECENT DEVELOPMENT 282
17 QUESTIONNAIRE 283
18 RELATED REPORTS 286
Segmentation
Short Description
North America Molecular Point of Care Testing (Using NAAT), By Product (Instruments And Consumables And Reagents), Indication (Respiratory Infections Testing, Sexually Transmitted Infection (STI) Testing, Gastrointestinal Tract Infections Testing And Others), End User ( Laboratories, Hospitals, Clinics, Home Care, Ambulatory Centers, Assisted Living Facilities And Others), Mode Of Testing ( Prescription-Based Testing And OTC-Based Testing), Distribution Channel (Direct Sales, Third Party Distributors, Online Sales), Country (U.S. and Canada), Industry Trends and Forecast to 2028
Market Definition
Point of Care Testing (POCT) is characterized as testing which can be done close to the patient where a medical decision can be made immediately, including the results and monitoring. POCT devices now entering into clinical use are based on nucleic acid amplification technologies (NAAT), defined here as second-generation devices. These platforms generally have improved sensitivity, typically in the range of 60 to 90%, compared to first-generation POCTs, and require portable instrumentation with a footprint of approximately 30x30cm. These instruments are essentially used in the molecular detection of various disorders such as HIV, HPV, and respiratory disease through nucleic acid amplification techniques (NAAT) technology. NAAT allows the identification of pathogenic organisms by detecting their DNA or RNA.
In the global pandemic, attempt to synergize the sensitivity of NAATs and the ease of use of POCT assays, miniaturized NAAT-based POCT devices and assays were devised for faster screening and diagnosis of COVID-19, which also propel the growth of the market.
Molecular point-of-care testing's significant advantages include the rapid diagnosis process, treatment choice, monitoring, and prognosis. This will also help in operational decision-making and proper resource utilization.
Market Segmentation
North America molecular point of care testing (using NAAT) market is categorized into five notable segments which are based on product, indication, end user, mode of testing, and distribution channel.
On the basis of product, the North America molecular point of care testing (using NAAT) market is segmented into instruments, consumables, and reagents
On the basis of indication, the North America molecular point of care testing (using NAAT) market is segmented into sexually transmitted infection (STI) testing, respiratory infection testing, gastrointestinal tract infection testing, and others
On the basis of end user, the North America molecular point of care testing (using NAAT) market is segmented into laboratories, hospitals, clinics, ambulatory centers, home care, assisted living facilities, and others
On the basis of mode of testing, the North America molecular point of care testing (using NAAT) market is segmented into prescription-based testing and OTC testing
On the basis of distribution channel, the North America molecular point of care testing (using NAAT) market is segmented into direct tender, third party distributor, and online sales
Market Players
Some of the key market players for North America molecular point of care testing (using NAAT) market are listed below:
Thermo Fisher Scientific Inc.
Hologic, Inc.
BD
F. Hoffmann-La Roche Ltd
ABBOTT
Seegene Inc.
bioMrieux SA
QIAGEN
Bio-Rad Laboratories, Inc.
PerkinElmer Inc.
Grifols, S.A.
Quidel Corporation
GenMark Diagnostics, Inc.
SD Biosensor, INC.
Oxford Nanopore Technologies
Wondfo
Randox Laboratories Ltd.
Meridian Bioscience
Sekisui Diagnostics
QuantuMDx Group Ltd.
Lucira Health Inc.
binx health, inc.
Sysmex (A Subsidiary of Sysmex Corporation)
Co-Diagnostics, Inc.
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.